E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced solid tumors |
Tumori solidi avanzati |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced solid tumors |
Tumori solidi avanzati |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059515 |
E.1.2 | Term | Non-small cell lung cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027481 |
E.1.2 | Term | Metastatic melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To assess antitumor activity of BA3021 alone and in combination with nivolumab. • To assess the safety of BA3021 alone and in combination with nivolumab. |
• Valutare l'attività antitumorale di BA3021 da solo e in combinazione con nivolumab. • Valutare la sicurezza di BA3021 da solo e in combinazione con nivolumab. |
|
E.2.2 | Secondary objectives of the trial |
• To further characterize the clinical activity of BA3021 alone and in combination with nivolumab.
Exploratory: • To assess the PK of BA3021 alone and in combination with nivolumab. • To evaluate the immunogenicity of BA3021 alone and in combination with nivolumab. • To explore the relationship between tumor receptor tyrosine kinase orphan receptor 2 (ROR2) status and clinical response to BA3021. • To evaluate potential candidate tumor and blood-based biomarkers for patient selection or correlation with antitumor activity of BA3021. |
• Caratterizzare ulteriormente l'attività clinica di BA3021 da solo e in combinazione con nivolumab.
Esplorativo: • Valutare la PK di BA3021 da solo e in combinazione con nivolumab. • Valutare l'immunogenicità di BA3021 da solo e in combinazione con nivolumab. • Esplorare la relazione tra lo stato del recettore orfano 2 della tirosin-chinasi tumorale (ROR2) e la risposta clinica a BA3021. • Valutare potenziali biomarcatori tumorali ed ematici candidati alla selezione dei pazienti o alla correlazione con l'attività antitumorale di BA3021. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must: - Have histologically or cytologically confirmed locally advanced unresectable or metastatic NSCLC or melanoma; - Age > = 18 Year; - Adequate renal function - Adequate liver function; - Adequate hematological function; - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy of at least three months
For the full list please see the protocol |
I pazienti devono: - Avere un NSCLC o un melanoma istologicamente o citologicamente confermato localmente avanzato, non resecabile o metastatico; - Età > = 18 anni; - Funzionalità renale adeguata - Adeguata funzionalità epatica; - Funzione ematologica adeguata; - Avere un performance status di 0 o 1 dell'Eastern Cooperative Oncology Group (ECOG). - Aspettativa di vita di almeno tre mesi
Per l'elenco completo consultare il protocollo |
|
E.4 | Principal exclusion criteria |
- Clinically significant cardiac disease; - Known non-controlled central nervous system (CNS) metastasis; - Prior therapy with a conjugated or unconjugated auristatin derivative / vinca-binding site targeting payload; - A history of allergic reactions to mAb therapy of grade equal to 3 or higher as well as known or suspected allergy or intolerance to any agent given during this study. - Major surgery within 4 weeks before first BA3011 administration; - Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); - Women who are pregnant or breast feeding
For the full list please see the protocol |
- Malattia cardiaca clinicamente significativa; - Metastasi del sistema nervoso centrale (SNC) note e non controllate; - Terapia precedente con un derivato dell'auristatina coniugato o non coniugato / carico utile mirato al sito di legame della vinca; - Anamnesi di reazioni allergiche di grado uguale o maggiore a 3 alla terapia con mAb, nonché allergia o intolleranza nota o sospetta a qualsiasi agente somministrato durante questo studio. - Intervento chirurgico maggiore nelle 4 settimane precedenti la prima somministrazione di BA3011; - Anamnesi nota di positività al virus dell'immunodeficienza umana (HIV) o di sindrome da immunodeficienza acquisita (AIDS); - Donne in gravidanza o in fase di allattamento
Per l'elenco completo consultare il protocollo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Efficacy: ORR. • Safety: AEs, SAEs, and changes from baseline in laboratory parameters and vital signs. |
- Efficacia: ORR. - Sicurezza: AEs, SAEs e variazioni rispetto al basale dei parametri di laboratorio e dei segni vitali. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Objective response rate (ORR) is defined as the proportion of subjects with a best overall response of confirmed CR or confirmed PR that occur prior to the initiation of subsequent anticancer treatment. |
Il tasso di risposta obiettiva (ORR) è definito come la proporzione di soggetti con una migliore risposta globale di CR o PR confermata che si verifica prima dell'inizio di un successivo trattamento antitumorale. |
|
E.5.2 | Secondary end point(s) |
Efficacy: o DOR o PFS o BOR o DCR o TTR o OS o Percent change from baseline in tumor size |
Efficacia: o DOR o PFS o BOR o DCR o TTR o OS o Variazione percentuale rispetto al basale delle dimensioni del tumore |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
DOR is defined as the time from the first documented OR until the first documented disease progression or death, whichever occurs first. PFS is defined as the time from the first dose of IP until the first documentation of disease progression or death. BOR will be based on all post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy. DCR is defined as the proportion of pts with a best overall response of confirmed CR, confirmed PR, or stable disease (SD)= 12 weeks. Duration of SD is defined as the time from the first dose of IP until the first documentation of disease progression or death. TTR is defined as the time from the first dose of IP until the first documentation of OR. OS is defined as the time from the first dose of BA3021 until death. |
DOR è tempo dal primo OR fino a primo progressione della malattia o morte, a seconda dell'evento che si verifica per primo. PFS è tempo da prima dose di IP fino a prima documentazione progressione malattia o Morte. BOR si baserà su tutte le valutazioni malattia post-basale che si verificano prima all'inizio della successiva terapia antitumorale. DCR la proporzione di pazienti con una migliore risposta complessiva di CR confermata, PR confermata o malattia stabile (DS)= 12 settimane. La durata di DS è definita come il tempo dal primo dose di IP fino alla prima documentazione della progressione della malattia o della morte. TTR è definito come il tempo dalla prima dose di IP fino alla prima documentazione di OR. La OS è definita come il tempo dalla prima dose di BA3021 fino alla morte |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Therapeutic exploratory |
Terapeutico esplorativo |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 46 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Hong Kong |
Taiwan |
United States |
France |
Poland |
Spain |
Germany |
Greece |
Italy |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |